反应详情

The title compound was prepared in a manner similar to EXAMPLE 3 using 2-chloro-5-(4-(methylsulfonyl)benzyl)-5,6,6a,7,9,10-hexahydro-[1,4]oxazino[3,4-h]pteridine (PREPARATION x9, 50 mg, 0.127 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (61.6 mg, 0.253 mmol) and PdCl2(dppf) (4.63 mg, 6.33 μmol) in dioxane (2 mL) and aqueous saturated NaHCO3 (0.4 mL). 1H NMR (400 MHz, DMSO-d6) δ 3.22 (m, 4 H), 3.48-3.55 (m, 1 H), 3.57-3.68 (m, 1 H), 3.93-4.05 (m, 2 H), 4.07-4.17 (m, 1 H), 4.68-4.79 (m, 3 H), 7.00-7.09 (m, 1 H), 7.21-7.30 (m, 1 H), 7.44-7.50 (m, 1 H), 7.52-7.58 (m, 1 H), 7.60-7.71 (m, 4 H), 7.90-7.98 (m, 2 H), 11.44-11.51 (m, 1 H). ESI-MS m/z [M+H]+ calc'd for C25H23N5O3S, 476.17; found 476.4.